Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 7/20 | 0.41 |
| ▸ | DRD1 | P21728 | 7/20 | 0.41 |
| ▸ | DRD4 | P21917 | 7/20 | 0.41 |
| ▸ | DRD5 | P21918 | 7/20 | 0.41 |
| ▸ | DRD3 | P35462 | 7/20 | 0.41 |
| ▸ | GLB1 | P16278 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17358471 | 0.93 | DRD2 (0.52) | DRD2SLC6A4DRD3SLC18A3SIGMAR1 | |
| SCHEMBL15873516 | 0.86 | KCNH2 (0.38) | DRD2SLC6A4SLC18A3SIGMAR1 | |
| SCHEMBL15873565 | 0.84 | PAX8 (0.41) | DRD2SLC6A4SLC18A3SIGMAR1 | |
| SCHEMBL15873605 | 0.82 | PER2 (0.43) | DRD2SLC6A4 | |
| SCHEMBL15875726 | 0.82 | SIGMAR1 (0.40) | DRD2SLC6A4SLC18A3SIGMAR1 | |
| SCHEMBL15873566 | 0.82 | SIGMAR1 (0.40) | DRD2SLC6A4SLC18A3SIGMAR1 | |
| SCHEMBL15873542 | 0.82 | SLC18A3 (0.44) | DRD2SLC18A3SIGMAR1 | |
| SCHEMBL17358472 | 0.81 | HTR6 (0.40) | DRD2SLC6A4 | |
| SCHEMBL17358483 | 0.81 | PER2 (0.38) | DRD2SLC6A4SLC18A3SIGMAR1 | |
| SCHEMBL17358485 | 0.79 | SLC18A3 (0.56) | SLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908863-B2 | Piperidinylcarbazoles | MERCK PATENT GMBH (DE) | 2018-03-06 | — | — | US | disclosed |
| US-20150368226-A1 | PIPERIDINYLCARBAZOLES | MERCK PATENT GMBH (DE) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368226-A1 | PIPERIDINYLCARBAZOLES | PSEN1, ARG2, UQCRC1 | DRD2 3092/4885SLC6A4 4186/4885HTR1A 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.